Funds holding “Halozyme Therapeutics Inc”
Which closed-end funds own a security? Searches the latest N-PORT snapshot of every active fund. Enter a ticker (issuer-level: matches the vendor-mapped ticker), a CUSIP or ISIN (security-level: one specific bond or share class), or part of a name.
17 positions across 15 funds, 4 distinct securities (bonds, share classes and derivatives of the same issuer are listed separately). Weights are percent of net assets from each fund’s latest N-PORT; report dates differ by fund.
| Fund | Position | Identifier | Type | Weight | Value (USD) | Report date | Coverage |
|---|---|---|---|---|---|---|---|
| BCV Bancroft Fund U.S. Equity | HALOZYME THERAPEUTICS INC | 40637HAJ8 | DBT | 2.30% | $4.4M | Jun 30, 2026 | full (88 positions) |
| GCV Gabelli Convertible & Income Securities Fund Convertible Securities | HALOZYME THERAPEUTICS INC | 40637HAJ8 | DBT | 1.92% | $1.9M | Jun 30, 2026 | full (121 positions) |
| ECF Ellsworth Growth & Income Fund U.S. Equity | HALOZYME THERAPEUTICS INC | 40637HAJ8 | DBT | 1.89% | $4.4M | Jun 30, 2026 | full (99 positions) |
| GRX Gabelli Healthcare & WellnessRx Trust Healthcare | HALOZYME THERAPEUTICS INC | 40637H109 | EC | 1.48% | $3.4M | Jun 30, 2026 | full (195 positions) |
| CPZ Calamos Long/Short Equity & Dynamic Income Trust U.S. Equity | Halozyme Therapeutics Inc | 40637H109 | EC | 1.37% | $3.5M | Jul 31, 2026 | full (761 positions) |
| ASG Liberty All Star Growth Fund U.S. Equity | Halozyme Therapeutics Inc | 40637H109 | EC | 0.65% | $2.6M | Jun 30, 2026 | full (119 positions) |
| NCZ Virtus Convertible & Income Fund II Convertible Securities | HALOZYME THERAPEUTICS INC | 40637HAG4 | DBT | 0.54% | $2.5M | Jul 31, 2026 | full (211 positions) |
| NCV Virtus Convertible & Income Fund Convertible Securities | HALOZYME THERAPEUTICS INC | 40637HAG4 | DBT | 0.52% | $3.1M | Jul 31, 2026 | full (210 positions) |
| ACV Virtus Diversified Income & Convertible Fund Convertible Securities | HALOZYME THERAPEUTICS INC | 40637HAG4 | DBT | 0.49% | $1.9M | Jul 31, 2026 | full (281 positions) |
| BMEZ BlackRock Health Sciences Term Trust Healthcare | Halozyme Therapeutics Inc | 40637H109 | EC | 0.46% | $4.9M | Jun 30, 2026 | full (170 positions) |
| AVK Advent Convertible & Income Fund Convertible Securities | HALOZYME THERAPEUTICS INC | 40637HAJ8 | DBT | 0.34% | $2.5M | Jul 31, 2026 | full (466 positions) |
| NIE Virtus Equity & Convertible Income Fund Convertible Securities | HALOZYME THERAPEUTICS INC | 40637HAG4 | DBT | 0.31% | $2.5M | Jul 31, 2026 | full (164 positions) |
| NFJ Virtus Dividend, Interest & Premium Strategy Fund U.S. Equity | HALOZYME THERAPEUTICS INC | 40637HAG4 | DBT | 0.16% | $2.4M | Jul 31, 2026 | full (170 positions) |
| AVK Advent Convertible & Income Fund Convertible Securities | HALOZYME THERAPEUTICS INC | 40637HAF6 | DBT | 0.15% | $1.1M | Jul 31, 2026 | full (466 positions) |
| GGZ Gabelli Global Small & Mid Cap Value Trust Global Equity | HALOZYME THERAPEUTICS INC | 40637H109 | EC | 0.14% | $235K | Jun 30, 2026 | full (321 positions) |
| VGI Virtus Global Multi-Sector Income Fund Multi-Asset | HALOZYME THERAPEUTICS INC | 40637HAJ8 | DBT | 0.02% | $22K | May 29, 2026 | full (758 positions) |
| VGI Virtus Global Multi-Sector Income Fund Multi-Asset | HALOZYME THERAPEUTICS INC | 40637HAF6 | DBT | 0.01% | $11.7K | May 29, 2026 | full (758 positions) |
Matching position names
Historical holdings reports are not a real-time portfolio. Security-level matching (CUSIP/ISIN) distinguishes a company’s bonds, common shares, preferreds and derivatives; issuer-level matching groups them by name or ticker and is labelled as such. See the overlap tool to compare two portfolios.